"Fluorenes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of diphenylenemethane derivatives.
| Descriptor ID |
D005449
|
| MeSH Number(s) |
D02.455.426.559.847.389 D04.615.389
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Fluorenes".
Below are MeSH descriptors whose meaning is more specific than "Fluorenes".
This graph shows the total number of publications written about "Fluorenes" by people in this website by year, and whether "Fluorenes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 3 | 0 | 3 |
| 2017 | 13 | 11 | 24 |
| 2018 | 14 | 5 | 19 |
| 2019 | 3 | 1 | 4 |
| 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Fluorenes" by people in Profiles.
-
Repurposing nonnucleoside antivirals against SARS-CoV2 NSP12 (RNA dependent RNA polymerase): In silico-molecular insight. Biochem Biophys Res Commun. 2021 09 24; 571:26-31.
-
Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication. Cells. 2021 04 29; 10(5).
-
Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial. Acta Biomed. 2020 11 10; 91(4):e2020102.
-
SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain. J Hepatol. 2020 11; 73(5):1262-1263.
-
Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Res. 2020; 9:129.
-
Shortened 8-Week Course of Sofosbuvir/Ledipasvir Therapy in Adolescents With Chronic Hepatitis C Infection. J Pediatr Gastroenterol Nutr. 2019 11; 69(5):595-598.
-
Design, synthesis of 4,5-diazafluorene derivatives and their anticancer activity via targeting telomeric DNA G-quadruplex. Eur J Med Chem. 2019 Sep 15; 178:484-499.
-
Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. J Hepatol. 2019 09; 71(3):473-485.
-
Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients. Saudi J Gastroenterol. 2019 Jan-Feb; 25(1):55-60.
-
Successful Treatment With Ledipasvir/Sofosbuvir in an Infant With Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency With HCV Allowed Gene Therapy with Strimvelis. Hepatology. 2018 12; 68(6):2434-2437.